210 related articles for article (PubMed ID: 24743709)
1. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Ediebah DE; Coens C; Zikos E; Quinten C; Ringash J; King MT; Schmucker von Koch J; Gotay C; Greimel E; Flechtner H; Weis J; Reeve BB; Smit EF; Taphoorn MJ; Bottomley A
Br J Cancer; 2014 May; 110(10):2427-33. PubMed ID: 24743709
[TBL] [Abstract][Full Text] [Related]
2. Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer.
Saranya K; Sreejith K; Ajaykumar
J Oncol Pharm Pract; 2019 Dec; 25(8):1853-1859. PubMed ID: 30616471
[TBL] [Abstract][Full Text] [Related]
3. Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Kristensen A; Solheim TS; Fløtten Ø; Grønberg BH
Acta Oncol; 2018 Nov; 57(11):1574-1579. PubMed ID: 30074418
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
5. [Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
Barlési F; Barrau K; Doddoli C; Morange S; Thirion X; Astoul P; Auquier P; Thomas P
Rev Mal Respir; 2006 Nov; 23(5 Pt 1):489-96. PubMed ID: 17314754
[TBL] [Abstract][Full Text] [Related]
6. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH; Sundstrøm S; Kaasa S; Bremnes RM; Fløtten O; Amundsen T; Hjelde HH; Plessen Cv; Jordhøy M
Eur J Cancer; 2010 Aug; 46(12):2225-34. PubMed ID: 20471248
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and quality of life in NSCLC PS 2 patients.
Helbekkmo N; Strøm HH; Sundstrøm SH; Aasebø U; Von Plessen C; Bremnes RM;
Acta Oncol; 2009; 48(7):1019-25. PubMed ID: 19274496
[TBL] [Abstract][Full Text] [Related]
8. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
[TBL] [Abstract][Full Text] [Related]
10. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
11. Measurement of health-related quality of life during chemotherapy - the importance of timing.
Kristensen A; Solheim TS; Amundsen T; Hjelde HH; Kaasa S; Sørhaug S; Grønberg BH
Acta Oncol; 2017 May; 56(5):737-745. PubMed ID: 28117614
[TBL] [Abstract][Full Text] [Related]
12. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
16. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
Ediebah DE; Quinten C; Coens C; Ringash J; Dancey J; Zikos E; Gotay C; Brundage M; Tu D; Flechtner HH; Greimel E; Reeve BB; Taphoorn M; Reijneveld J; Dirven L; Bottomley A;
Cancer; 2018 Aug; 124(16):3409-3416. PubMed ID: 29905936
[TBL] [Abstract][Full Text] [Related]
17. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
18. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
19. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Fiteni F; Anota A; Bonnetain F; Oster JP; Pichon E; Wislez M; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Molinier O; Dansin E; Poudenx M; Milleron B; Morin F; Zalcman G; Quoix E; Westeel V
Eur Respir J; 2016 Sep; 48(3):861-72. PubMed ID: 27338193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
